Union health minister Mansukh Mandaviya on Tuesday launched the National Policy on Research and Development and Innovation in Pharma-MedTech Sector in India and Scheme for promotion of Research and Innovation in Pharma MedTech Sector (PRIP).
Accentuating the benefits of the scheme, Dr Mansukh Mandaviya noted the scheme will focus on transforming India into a high-volume, high-value player in the global market of pharmaceuticals, meeting the quality, accessibility, and affordability goals. He further stated “The policy will help to create an ecosystem of skills and capacities including the academia and the private sectors, and give impetus to new talent among the youth through start-ups.”
This is a transformative stage in the Indian drugs and med-tech sector, he stressed where synergies are being created between various Government institutions and agencies such as Pharma Deptt., ICMR, DST, DBT, NIPER etc.
Reiterating the slogan of ‘Jai Jawan, Jai Kisan, Jai Vigyan and Jai Anusandhan’, he elaborated that India prioritizes growth and innovation in brain power and manpower, wherein Covid is an example where we stood the testimony of the time. We need to do mass production of our pharmaceutical products and medical devices. For this, we have made three bulk drug parks in Himachal Pradesh, Vizag and Gujarat and four medical device parks in Himachal Pradesh, Uttar Pradesh, Madhya Pradesh and Tamil Nadu, which will help in strengthening this sector.
As per the allocation of Business Rules, the Department of Pharmaceuticals has been assigned, amongst others, the work related to promotion and co-ordination of basic, applied and other research in areas related to the pharmaceutical sector; education and training including high end research; international co-operation in pharmaceutical research, inter- sectoral coordination and all matters relating to National Institutes of Pharmaceutical Education and Research (NIPERs).